Latest news

• AZ expects return to growth this year after 2017 decline

  Mantle cell lymphoma therapy Calquence has a long way to go before it can challenge main rival Imbruvica (ibrutinib) from Johnson &Johnson/AbbVie, but according to AZ is picking up 20%

• Celgene gains French reimbursement for Revlimid in multiple myeloma

  It’s been approved in combination with dexamethasone as a first-line treatment for multiple myeloma in patients who are not eligible for autologous stem cell transplant. ... However, HAS handed Revlimid ASMR V status, equating to ‘no

• Janssen's Imbruvica fails to win NICE backing in lymphoma

  Janssen's Imbruvica fails to win NICE backing in lymphoma. But the agency recommends it on the CDF for another type of cancer. ... Draft guidance from the cost-effectiveness body doesn’t back Imbruvica to treat mantle cell lymphoma (MCL) - an incurable,

• AbbVie and Roche plan Venclexta combo filings in leukaemia

  AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML), picking up a breakthrough designation from the FDA ... 8bn last year in CLL, mantle cell lymphoma (MCL), Waldenström

• Clock starts ticking on FDA review of AZ's acalabrutinib

  The FDA has started its review of AstraZeneca's BTK inhibitor acalabrutinib, shortly after granting the drug a breakthrough designation for relapsed or refractory mantle cell lymphoma (MCL). ... The BTK inhibitor is designed to interrupt the signalling